Amylin stock up nearly 14% on acquisition rumours
This article was originally published in Scrip
Executive Summary
Amylin Pharmaceuticals' stock price jumped by 13.7% to a recent high of $26.06 per share on 23 April on rumours that the company behind the two-drug exenatide franchise for the treatment of type 2 diabetes is looking for a buyer.